Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06631287 · ClinicalTrials.gov registry record · Phase 3
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
A Phase 3 study of COVID-19 and Long COVID, sponsored by Wes Ely.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
- 16
- Study locations
NCT06631287 is a Phase 3 study of COVID-19 and Long COVID that is actively recruiting participants, run by Wes Ely. The registered enrollment target is 550 participants, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT06631287, a Phase 3 study of COVID-19 and Long COVID, is actively recruiting participants, sponsored by Wes Ely.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
- 16
- Study locations
Study Summary
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Baricitinib
Study Locations (16)
California
- University of California, Los Angeles (UCLA) - Los Angeles
- University of California San Francisco - San Francisco
Ohio
- University Hospitals Cleveland Case Western - Cleveland
- The MetroHealth System - Cleveland
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado I Anschutz Medical Campus - Aurora
Connecticut
- Yale University - New Haven
Florida
- University of Florida College of Medicine - Gainesville
Georgia
- Emory University - Atlanta
Illinois
- Illinois Research Network (ILLInet), University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06631287
The ClinicalTrials.gov registry entry for NCT06631287 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is Wes Ely, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06631287 reports 16 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT06631287 about?
NCT06631287 is a clinical study titled "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID". The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomark...
What is the current status of trial NCT06631287?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2024-10-21. Estimated completion is 2027-07-01.
What conditions does trial NCT06631287 study?
This clinical trial studies the following conditions: COVID-19, Long COVID, SARS CoV 2 Infection, Coronavirus Infections.
What interventions are being tested in trial NCT06631287?
The interventions under investigation include: Placebo (OTHER), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT06631287?
This trial is sponsored by Wes Ely, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06631287 being conducted?
This trial has 16 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
-
Study of VYD2311 for the Prevention of COVID-19
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.